Chief Executive Officer of Pune based Serum Institute of India Adar Poonawalla on Wednesday clarified that the COVID-19 vaccine Covovax is available for everyone above the age of 12 years.
"A lot of you have asked if Covovax is available for adults. The answer is yes, it is available for everyone above the age of 12," Poonawalla tweeted.
This comes a day after Poonawalla announced on Twitter that Covovax is now available for children in India.
Covovax (Novavax), is now available for children in India. This is the only vaccine manufactured in India that is also sold in Europe and has an efficacy of 90 per cent. This is in line with Prime Minister Narendra Modi's vision of providing yet another vaccine to protect our children," he said in a tweet.
Last week, the National Technical Advisory Group on Immunisation (NTAGI) approved the Serum Institute of India's Covovax COVID-19 vaccine for the age group 12-17.
Last year in December, the government cleared Covovax for restricted use in an emergency situation.
Meanwhile, many Twitterati complained that the Covovax option is not available on CoWIN app for 18 + vaccine beneficiaries.
"The Cowin doesn't make Covovax an option if 18 and above tab is selected. Hopefully, that will be looked into," a user said.
While, another user posted a screenshot of CoWIN app and said, "Check this out, when we select 18 & above option in CoWIN app, automatically Covovax option gets faded i.e disabled while 4 other options are highlighted i.e Covishield, Covaxin, Sputnik, ZyCov-D.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.